Crescent Biopharma, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CBIO | PBYI | CGEM | NBP | BBOT | CHRS | |
|---|---|---|---|---|---|---|
| Market cap | 513.37M | 551.82M | 767.61M | 117.16M | 184.40M | 131.36M |
| P/E (TTM) | — | 21.0 | — | — | — | — |
| Forward P/E | -5.3 | 30.5 | -5.1 | -0.8 | -0.8 | -1.3 |
| Price/book | 2.9 | 3.9 | 2.5 | 0.6 | 0.6 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +5.50% | +118.16% | +69.93% | −75.89% | −81.22% | −42.95% |
| Today | +5.82% | +4.60% | −20.70% | 0.00% | −0.86% | +5.54% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CBIO news ›Reviewing Crescent Biopharma (NASDAQ:CBIO) and Lyell Immunopharma (NASDAQ:LYEL)
Posted by Sarita Garza on Oct 31st, 2026 Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) and Crescent Biopharma (NASDAQ:CBIO – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will…
H.C. Wainwright Keeps Their Buy Rating on Coherus Biosciences (CHRS)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Coherus Biosciences today and set a price target of $7.00. Tsao covers the Healthcare sector, focusing on stocks such as Argenx Se, Alkermes, and Disc Medicine. According to…
Connect Biopharma’s (CNTB) Buy Rating Reiterated at HC Wainwright
Posted by Danessa Lincoln on Oct 28th, 2026 Connect Biopharma (NASDAQ:CNTB – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. Read Our…
More from 1 other outlet
Bank of America Securities Keeps Their Buy Rating on HUTCHMED (HCM)
In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on HUTCHMED, with a price target of $18.00. Stranahan covers the Healthcare sector, focusing on stocks such as Moderna, Revolution…
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Now Rated “Moderate Buy” by Wall Street Analysts
Read Our Latest Stock Report on Corbus Pharmaceuticals Shares of NASDAQ:CRBP opened at $4.05 on Friday. Corbus Pharmaceuticals has a 1 year low of $3.93 and a 1 year high of $18.11. The business has a fifty day simple moving average of…
HC Wainwright & Co. reiterates Buy rating on Microbot Medical, $12 price target
TradingView HC Wainwright & Co. reiterates Buy rating on Microbot Medical, $12 price target HC Wainwright & Co. reiterated their Buy rating on Microbot Medical's stock with a price target of $12.00. The price target imp
HC Wainwright Reaffirms “Buy” Rating for Crescent Biopharma (NASDAQ:CBIO)
Crescent Biopharma (NASDAQ:CBIO – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Monday, Marketbeat reports. They presently have a $36.00 price target on the…
Crescent Biopharma CR-002 trial on track for Q4 2026
FDA clears CR-002 for human testing as Crescent Biopharma (CBIO) prepares to start its trial. Stock Titan Crescent Biopharma CR-002 trial on track for Q4 2026 ASCEND’s chemotherapy expansion includes first-line and later-line regimens…
Crescent Biopharma advances cancer trials with CR-001 combos, targets Phase 3 start in early 2028
Crescent Biopharma is progressing its clinical trials for CR-001, a PD-1 x VEGF bispecific antibody, enrolling patients globally in combination with standard chemotherapy for various cancers. The company expects to report initial…
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
Crescent and Kelun-Biotech have achieved seven clearances to begin clinical testing, with multiple portfolio readouts expected in 2027. First ASCEND patient dosed; company outlined planned proof-of-concept data in Q1 2027. More than 125…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- defenseworld.net5
- themarketsdaily.com3
- markets.businessinsider.com2
- stocktitan.net2
- tradingview.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 15 articles, not a forecast.